What are the contraindications to Wegovy (semaglutide)?

Contraindications to Wegovy (Semaglutide)

Wegovy is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), and in those with prior serious hypersensitivity reactions to semaglutide or its excipients. 1

Absolute Contraindications

Based on FDA labeling and clinical guidelines, the following are absolute contraindications:

1. Thyroid-Related Contraindications

• Personal history of medullary thyroid carcinoma (MTC) - This is based on animal studies showing thyroid C-cell tumors with GLP-1 receptor agonists 2
• Family history of MTC - First-degree relatives with MTC constitute an absolute contraindication 1
• Multiple endocrine neoplasia syndrome type 2 (MEN 2) - Patients with this genetic syndrome are at high risk for MTC 3, 1

2. Hypersensitivity Reactions

• Prior serious hypersensitivity to semaglutide - Including anaphylaxis or angioedema 1
• Prior serious hypersensitivity to any excipients in Wegovy 1

Important Clinical Precautions (Not Absolute Contraindications, But Require Careful Consideration)

While not absolute contraindications per FDA labeling, the following warrant extreme caution or avoidance:

Pregnancy

• Contraindicated in pregnancy based on research evidence 4
• Should be discontinued at least 2 months before planned pregnancy due to long half-life

History of Pancreatitis

• Not listed as an absolute contraindication in FDA labeling, but GLP-1 receptor agonists are associated with increased risk of pancreatitis 2
• The 2023 JAMA guideline notes pancreatitis as a precaution but explicitly states it is not a contraindication for liraglutide (another GLP-1 RA) 3
• Use clinical judgment; active pancreatitis should prompt avoidance

Severe Gastroparesis

• Wegovy is not recommended in patients with severe gastroparesis due to delayed gastric emptying effects 1

History of Suicidal Behavior

• FDA recommends avoiding Wegovy in patients with history of suicidal attempts or active suicidal ideation 1

Common Pitfalls to Avoid

1. Confusing precautions with contraindications: History of pancreatitis, diabetic retinopathy, or cardiovascular disease are monitoring considerations, not absolute contraindications

2. Overlooking family history: Always ask specifically about family history of thyroid cancer, not just personal history

3. Missing MEN 2 syndrome: Screen for other endocrine tumors (pheochromocytoma, parathyroid adenomas) that suggest MEN 2

4. Ignoring prior GLP-1 RA reactions: If a patient had anaphylaxis to another GLP-1 receptor agonist (liraglutide, dulaglutide), use extreme caution as cross-reactivity may occur 1

Clinical Algorithm for Screening

Before prescribing Wegovy, systematically assess:

1. Personal thyroid cancer history → If MTC present, do not prescribe
2. Family history of thyroid cancer → If MTC in first-degree relative, do not prescribe
3. Known MEN 2 syndrome → Do not prescribe
4. Prior hypersensitivity to semaglutide → Do not prescribe
5. Pregnancy status or planning → Do not prescribe
6. Active suicidal ideation → Avoid
7. Severe gastroparesis → Avoid

The evidence is clear and consistent across FDA labeling 1 and major clinical guidelines 3, 2 regarding the two absolute contraindications: MTC/MEN 2 history and prior serious hypersensitivity reactions.